Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) has delivered a remarkable 137.52% gain over the past year, though the stock has pulled back 6.12% year-to-date and sits 7.20% below its one-month high, currently trading near $72.70. The stock remains well off its 52-week high of $86.74, with the Street’s consensus target sitting at $93.90 across 22 analysts.

Barclays stands apart from the pack, raising its price target to $106 from $95 while maintaining an Overweight rating on the shares. That target represents roughly 46% upside from current levels and sits meaningfully above the Street’s average. But can IONS realistically reach $106 by the end of 2026?

Barclays’ $106 IONS Prediction

The Barclays thesis centers on a single underappreciated asset. The firm boosted its 2034 Tryngolza estimate for severe hypertriglyceridemia (sHTG) to $4 billion in the U.S., supported by what it describes as “supportive” physician checks. Barclays argues that severe hypertriglyceridemia is the most important near-term opportunity for Ionis and remains underappreciated by the market. The sNDA for olezarsen in sHTG carries a PDUFA target date of June 30, 2026, making the catalyst timeline concrete and near-term.

Key Drivers of IONS Stock Performance

1. Olezarsen’s broad sHTG launch opportunity: The sHTG label targets a broad patient population, expanding well beyond the narrow familial chylomicronemia syndrome indication covered by Tryngolza. Phase 3 CORE and CORE2 trials demonstrated up to 72% placebo-adjusted reduction in fasting triglycerides and an 85% reduction in acute pancreatitis events, a clinical profile that supports premium pricing and durable revenue compounding for retirement portfolios.
2. Tryngolza’s accelerating commercial trajectory: Net product sales hit $50 million in Q4 2025, a 56% sequential increase, with full-year 2025 sales of $108 million. That ramp from $6 million in Q1 to $50 million in Q4 demonstrates the kind of launch execution that builds long-term royalty and revenue durability.
3. Pipeline catalysts stacked through 2026: Zilganersen for Alexander disease received FDA Priority Review with a PDUFA date of September 22, 2026. Mid-year data from the pelacarsen Lp(a) HORIZON cardiovascular outcomes trial and the eplontersen CARDIO-TTRansform trial in H2 2026 provide multiple shots at value creation for long-term holders.

What Will It Take for IONS to Reach $106?

With 165.19 million shares outstanding, a $106 price target implies a market capitalization of roughly $17.5 billion. Achieving that requires regulatory approval for olezarsen in sHTG, early commercial uptake signaling the $4 billion peak sales potential Barclays envisions, and continued Tryngolza momentum. Ionis also needs to demonstrate progress toward its 2028 cash flow breakeven target while managing a projected year-end 2026 cash position of approximately $1.6 billion.

The primary risk is continued operating losses, with 2026 non-GAAP operating loss guidance of $500 to $550 million, meaning the bull case depends almost entirely on execution. For retirement investors with a multi-year horizon, the convergence of a near-term binary catalyst, a validated commercial platform, and a $4 billion long-term revenue estimate makes Barclays’ $106 target a credible destination.